10x Genomics
About: 10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Employees: 1,306
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
27% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 49
2% more funds holding
Funds holding: 262 [Q3] → 267 (+5) [Q4]
0.45% less ownership
Funds ownership: 98.37% [Q3] → 97.93% (-0.45%) [Q4]
3% less repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 89
31% less call options, than puts
Call options by funds: $1.4M | Put options by funds: $2.02M
36% less capital invested
Capital invested by funds: $2.36B [Q3] → $1.51B (-$858M) [Q4]
100% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 0 (-2) [Q4]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
Morgan Stanley Tejas Savant 22% 1-year accuracy 4 / 18 met price target | 139%upside $26 | Overweight Maintained | 14 Feb 2025 |
Barclays Luke Sergott 31% 1-year accuracy 16 / 52 met price target | 38%upside $15 | Overweight Maintained | 14 Feb 2025 |
Canaccord Genuity Kyle Mikson 46% 1-year accuracy 13 / 28 met price target | 65%upside $18 | Buy Maintained | 13 Feb 2025 |
Citigroup Patrick Donnelly 33% 1-year accuracy 10 / 30 met price target | 83%upside $20 | Buy Maintained | 13 Feb 2025 |
JP Morgan Rachel Vatnsdal 65% 1-year accuracy 11 / 17 met price target | 10%upside $12 | Neutral Maintained | 13 Feb 2025 |
Financial journalist opinion
Based on 15 articles about TXG published over the past 30 days
